Barb what you are being told comports with what Dr. Charles "Snuffy" Myers said in one of his weekly when Zytiga and Xtandi were new on the scene in 2012.
askdrmyers.wordpress.com/page/11/I just had occasion to re-read it during an on-line exchange with the Wampuscats. Here is an excerpt from Dr. Myers' article
"While it is approved for use after chemotherapy, Xtandi is a form of hormonal therapy. It works by disrupting the function of the androgen receptor through which testosterone and dihydrotestosterone exert their effects on prostate cancer. This drug works after chemotherapy fails because even at that stage between 80-90% of cancers are still dependent on the androgen receptor. The discovery of this fact is revolutionizing prostate cancer treatment. When drugs like Lupron and Casodex have failed, the cancer is not in fact hormone resistant. In fact, the cancer has adapted by becoming even more sensitive to testosterone. This cancer can change to grow at testosterone levels 1/100 to 1/1,000 of that found in a normal adult male. Lupron and Casodex fail because they are not powerful enough. Prostate cancer accomplishes this by several different mechanisms. Prostate cancer cells can make their own testosterone, making them independent of outside sources. The cells can increase the amount of androgen receptor so that it traps enough testosterone to continue to grow, like using a larger sail in a light wind. The cancer cells can also change the androgen receptor so that it treats Casodex or Eulexin as if it were testosterone, so that drugs that are used to block testosterone now act as if they were testosterone! This is why some patients respond when Casodex is stopped. Finally, the androgen receptor can be altered so that it is activated with little or no testosterone. The end result of all of this research is that we now know that it is quite uncommon for prostate cancer to become androgen independent. This led to a blossoming in research to find drugs able to restore hormone-responsiveness in men with advanced prostate cancer."
LupronJim